0.00%
0.14%
103.41%
67.29%
482.11%
-42.81%
-67.34%
AI Spotlight on GTHX
Company Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer.The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer.
In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer.The company has a license agreement with EQRx, Inc.and Genor Biopharma Co. Inc.
for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD.for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses.G1 Therapeutics, Inc.
was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Market Data
| Last Price | 7.16 |
| Change Percentage | 0.14% |
| Open | 7.15 |
| Previous Close | 7.15 |
| Market Cap ( Millions) | 378 |
| Volume | 1097310 |
| Year High | 7.19 |
| Year Low | 1.08 |
| M A 50 | 5.57 |
| M A 200 | 4.01 |
Financial Ratios
| FCF Yield | -9.94% |
| Dividend Yield | 0.00% |
| ROE | 26.28% |
| Debt / Equity | 180.21% |
| Net Debt / EBIDTA | -92.70% |
| Price To Book | 15.28 |
| Price Earnings Ratio | -8.39 |
| Price To FCF | -10.06 |
| Price To sales | 6.49 |
| EV / EBITDA | -11.59 |
News
- Sep -18 - Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
- Aug -09 - SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Primo Water Corporation – PRMW
- Aug -09 - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
- Aug -08 - G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
- Aug -08 - G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
- Aug -07 - Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
- Aug -07 - Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
- Aug -07 - Pharmacosmos Group to Acquire G1 Therapeutics
- Aug -01 - G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jul -25 - G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
- Jul -15 - G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
- Jul -10 - Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
- Jul -01 - G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
- Jun -24 - G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
- Jun -24 - Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
- Jun -24 - Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
- Jun -24 - G1 Therapeutics' breast cancer drug fails in late-stage trial
- Jun -24 - G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
- Jun -05 - G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May -28 - Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Small Molecule Therapeutics
Expected Growth : 12 %
What the company do ?
Novel Small Molecule Therapeutics from G1 Therapeutics, Inc. are oral therapies that target specific proteins to prevent chemotherapy-induced neutropenia and anemia.
Why we expect these perspectives ?
G1 Therapeutics' novel small molecule therapeutics drive 12% growth, fueled by increasing demand for targeted cancer treatments, advancements in precision medicine, and a strong pipeline of innovative compounds. Additionally, strategic partnerships and collaborations accelerate development, while a growing need for effective therapies in underserved patient populations further propels growth.
Segment n°2 -> License Revenue
Expected Growth : 16 %
What the company do ?
License Revenue from G1 Therapeutics, Inc. refers to the income generated from licensing its proprietary technology and intellectual property to other companies.
Why we expect these perspectives ?
G1 Therapeutics' 16% license revenue growth is driven by increasing adoption of its CDK4/6 inhibitor, trilaciclib, in breast cancer treatment. Strong partnerships with pharmaceutical companies, such as GSK and Simcere, have expanded its global reach. Additionally, the company's growing pipeline of oncology and non-oncology products is expected to contribute to future revenue growth.
G1 Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Trilaciclib | A CDK4/6 inhibitor for the treatment of patients with metastatic triple-negative breast cancer |
| Lerociclib | An oral, selective CDK4/6 inhibitor for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) breast cancer |
| G1T38 | An oral, selective CDK4/6 inhibitor for the treatment of patients with myeloid malignancies |
G1 Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
G1 Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and other diseases.
Bargaining Power Of Customers
G1 Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power among patients and healthcare providers.
Bargaining Power Of Suppliers
G1 Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services.
Threat Of New Entrants
G1 Therapeutics, Inc. has a high threat of new entrants due to the growing demand for cancer therapies and the presence of emerging biotech companies.
Intensity Of Rivalry
G1 Therapeutics, Inc. operates in a highly competitive industry with intense rivalry among established players and emerging companies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 59.89% |
| Debt Cost | 12.50% |
| Equity Weight | 40.11% |
| Equity Cost | 12.50% |
| WACC | 12.50% |
| Leverage | 149.30% |
G1 Therapeutics, Inc. : Quality Control
G1 Therapeutics, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OCUL | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company … |
| IMNM | Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of … |
| PSTX | Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) … |
| PRAX | Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive … |
| BCRX | BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ocular Therapeutix
A-Score
1-Year Total Return ->
🥈
Praxis Precision Medicines
A-Score
1-Year Total Return ->
🥉
BioCryst Pharmaceuticals
A-Score
1-Year Total Return ->
4
Poseida Therapeutics
A-Score
1-Year Total Return ->
5
G1 Therapeutics
A-Score
1-Year Total Return ->
6
